表紙
市場調査レポート

アレルギー性鼻炎治療薬市場の予測:抗ヒスタミン剤・コルチコステロイド・免疫療法・ワクチンにおける企業の将来展望

Allergic Rhinitis Drugs Market Forecast 2015-2025: Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines

発行 Visiongain Ltd 商品コード 310754
出版日 ページ情報 英文 326 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=137.27円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
アレルギー性鼻炎治療薬市場の予測:抗ヒスタミン剤・コルチコステロイド・免疫療法・ワクチンにおける企業の将来展望 Allergic Rhinitis Drugs Market Forecast 2015-2025: Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines
出版日: 2015年09月03日 ページ情報: 英文 326 Pages
概要

世界のアレルギー性鼻炎薬市場額は2014年に113億米ドルに達する見込みで、2015-2025年の期間中は収益成長が見込まれています。アレルギー性鼻炎薬の需要増加、医療保険適用範囲の拡大、経済的回復および免疫療法市場の成長が2025年まで売上を増加させる見込みです。

当レポートでは、世界のアレルギー性鼻炎薬市場について調査し、世界市場、主要国市場および2次市場の売上予測、製品別の収益予測、R&D動向、市場の課題、市場の展望および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 本書の概要

第2章 イントロダクション:アレルギー性鼻炎

  • 製薬産業:概要
  • アレルギーの概要
  • アレルギー性鼻炎
  • アレルギー性鼻炎の治療
  • 治験の段階
  • 調査範囲

第3章 アレルギー性鼻炎治療薬:世界市場

  • 世界のアレルギー性鼻炎治療薬市場
  • 市場の分類
  • 売上実績
  • 市場売上予測
  • セグメント別の市場シェア変化予測

第4章 鼻腔内抗ヒスタミン薬市場の分析および予測

  • 主要製品
  • 市場の動向・発展
  • 市場予測
    • 金額ベース
    • 数量ベース
  • 主な鼻腔内抗ヒスタミン薬
  • Patanase (olopatadine, Novartis)
  • Astepro (azelastine, Meda)
  • Astelin (azelastine, Meda)
  • Dymista (azelastine/fluticasone, Meda)
  • Generic Intranasal Azelastine
  • Generic Intranasal Olopatadine

第5章 鼻腔内コルチコステロイド薬市場の分析および予測

  • 主要製品
  • 市場予測
    • 数量ベース
    • 主要薬別市場シェア変化予測
  • 主な鼻腔内コルチコステロイド薬
  • Nasonex (mometasone, Merck)
  • Avamys/Veramyst (fluticasone furoate, GSK)
  • Flixonase/Flonase (fluticasone propionate, GSK)
  • Rhinocort (budesonide, AstraZeneca)
  • Omnaris (ciclesonide,大日本住友製薬/武田薬品工業)
  • Nasacort (triamcinolone, Sanofi)
  • Beconase/Beconase AQ (beclometasone, GSK/Omega Pharma)
  • QNasl (beclometasone, Teva)
  • Zetonna (ciclesonide, 大日本住友製薬)
  • Generic Intranasal Corticosteroids

第6章 経口抗ヒスタミン薬市場の分析および予測

  • 市場概要
  • 市場の動向・発展
  • 市場予測
    • 主要薬別市場シェア変化予測
  • 主な経口抗ヒスタミン薬
  • Allegra/Allegra-D/Allegra OTC (fexofenadine, Sanofi)
  • Zyrtec/Zyrtec D (cetirizine, Johnson & Johnson/UCB/GSK)
  • Claritin/Claritin OTC (loratadine, Merck & Co.)
  • Xyzal (levocetirizine, Sanofi/UCB/GSK)
  • Allelock (olopatadine, Kyowa Hakko Kirin)
  • Clarinex (desloratadine, Merck & Co.)
  • Ebastel (ebastine, Almirall/武田薬品工業/大日本住友製薬)
  • Talion (bepotastine, 田辺三菱製薬)
  • その他の経口抗ヒスタミン薬

第7章 免疫療法・ワクチン市場の分析および予測

  • 市場概要
  • 主な免疫療法製品
  • 市場の動向・発展
  • 市場予測
    • 主要薬別市場シェア変化予測
  • 投薬経路別免疫療法の種類
  • 主要製品
  • Staloral (Grass pollen allergen extract, Stallergenes)
  • Alutard SQ (Grass pollen allergen extract, ALK-Abello)
  • Grazax/Grastek (Timothy grass pollen allergen extract, ALK-Abello/Merck)
  • Oralair (Grass pollen allergen extract, Stallergenes/Greer)
  • Ragwitek (Short ragweed pollen allergen extract, Merck)
  • その他の免疫療法製品

第8章 主要国のアレルギー性鼻炎治療薬市場

  • 世界のアレルギー性鼻炎治療薬市場の地域的内訳
  • 主要国市場予測
    • 国別の市場シェア変化予測
  • 地域別市場の分析および予測
  • 米国市場:最大の市場
    • 動向・発展
    • 処方薬からOTC薬へ
    • 市場予測
  • EU5ヶ国
    • 市場予測
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
  • 中国市場
    • 大気汚染に関連したと有病率の上昇
    • 医療保険と医療費償還の拡大
    • 市場予測
  • 日本
    • 杉林の再生と花粉症の流行
    • 免疫療法としての遺伝子組み換え米
    • ジェネリック医薬品普及率の上昇効果
    • 市場予測
  • ロシア
    • ロシアの経済状況が医薬品産業に与える影響
    • 市場予測
  • インド
    • インドの医薬品産業における薬価管理法の影響
    • 医療保険の供給拡大
    • 市場予測
  • ブラジル
    • 医療保険の成長がアレルギー性鼻炎薬に与える影響
    • 市場予測
  • メキシコ
    • 多国籍企業はメキシコ市場の潜在力に気付いているか
    • 市場予測
  • その他の地域

第9章 アレルギー性鼻炎薬の主要企業

  • アレルギー性鼻炎薬:進化する市場空間
  • ALK-Abello
  • GSK
  • Johnson & Johnson
  • 協和発酵キリン
  • Merck & Co.
  • Sanofi
  • Stallergenes
  • UCB
  • その他の主要企業

第10章 アレルギー性鼻炎薬のパイプライン分析

  • 動向・発展
  • 経口抗ヒスタミン薬パイプライン
  • 鼻腔内コルチコステロイド薬パイプライン
  • 免疫療法パイプライン
  • その他のアレルギー性鼻炎薬のパイプライン

第11章 アレルギー性鼻炎薬市場の定性分析

  • アレルギー性鼻炎薬に影響を与える市場因子
  • SWOT分析
    • 強み
    • 弱み
    • 機会
    • 脅威
  • ポーターのファイブフォース分析

第12章 調査インタビュー

第13章 結論

  • 最新市場状況および市場予測
  • アレルギー性鼻炎薬市場の主要部門
  • アレルギー性鼻炎薬市場の主要地域
  • アレルギー性鼻炎薬の主要企業
  • アレルギー性鼻炎薬市場の将来

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0064

Allergic Rhinitis drugs - new study showing you trends, partnerships, and predicted revenues

Where is the market for allergic rhinitis drugs heading? What are the commercial prospects for this market? Visiongain's new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Our 326 page report provides 273 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess:

  • Forecasted sales at world market, submarket, regional and national level
  • You will see financial results and revenue predictions
  • Interviews, trends, opportunities

Forecasts from 2015-2025 and other analyses show you commercial prospects

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find:

  • Original analyses, with business outlooks and developments
  • Discover qualitative analyses (including SWOT and Porter's Five Forces)
  • Company profiles and commercial developments

Read the full transcript of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

  • Tonya Winders, President and CEO, Allergy & Asthma Network
  • Amena Warner, Nurse Advisor at Allergy UK and President, International Nurses Group in Immunodeficiencies
  • Dr Apelle Econs MRCS LRCP, Consultant - Allergy & Nutrition, Allergy Medical UK

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:

  • Oral antihistamines
  • Intranasal corticosteroids
  • Immunotherapy & Vaccines
  • Intranasal antihistamines
  • Other allergic rhinitis drugs

Additionally, our new study provides global sales forecasts by volume for the intranasal corticosteroids and intranasal antihistamines submarkets, including individual global sales forecasts by volume for the leading drugs in these submarkets from 2015-2025.

image1

Our investigation shows business research and analysis with individual revenue forecasts and discussions for each submarket.

See revenue forecasts for products

How will leading drugs perform to 2025 at world level? Our study forecasts sales of 25 marketed products, including these brands:

  • Claritin/ Claritin OTC
  • Allegra/ Allegra-D/ Allegra OTC
  • Staloral
  • Ragwitek
  • Nasonex
  • Omnaris
  • Patanase
  • Astepro
  • Clarinex

image2

Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?

You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.

  • US
  • China
  • Japan
  • Germany
  • India
  • France
  • UK
  • Italy
  • Spain
  • Brazil
  • Russia
  • Mexico
  • Rest of the World

Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.

Leading companies and potential for market growth

We expect the rising prevalence and the consequent increase in demand for allergic rhinitis drugs, expanding healthcare coverage, the strength of the R&D pipeline and developments in drug delivery technologies to contribute to an increase in sales for allergic rhinitis drugs to 2025.

Our work shows you what organisations hold greatest potential. See profiles of 8 leading companies, including these:

  • UCB
  • Sanofi
  • Kyowa Hakko Kirin
  • GlaxoSmithKline
  • ALK- Abelló
  • Stallergenes
  • Merck & Co
  • Johnson & Johnson

image3

A company profile gives you the following information:

  • Revenue forecast for allergic rhinitis drugs from 2015 to 2025
  • Recent financial results
  • Assessment of recent developments - mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
  • Discussion of a company's activities and outlook
  • Allergic rhinitis drugs revenue forecast from 2015 to 2025

Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?

Research and development activities - assess innovation, trends and possibilities

What is happening in the R&D pipeline for allergic rhinitis treatments? You see developmental trends, gaining insight into each segment of the allergic rhinitis drug R&D pipeline for:

  • Intranasal corticosteroids
  • Immunotherapy
  • Oral antihistamines
  • Other progress in allergic rhinitis

image4

Our study also discusses these agents and technologies, among others:

  • Subcutaneous immunotherapy
  • Sublingual immunotherapy tablets
  • Oral antihistamines
  • Intranasal corticosteroids
  • Novel small molecules including toll-like receptor antagonists

What issues will affect the allergic rhinitis drugs market?

Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting allergic rhinitis treatments. You will find discussions, including qualitative analyses:

  • A strong immunotherapy R&D pipeline
  • Patent expiries and generic competition
  • Pricing and reimbursement pressures created by government cost-cutting initiatives
  • Rx-to-OTC switching
  • Growth areas such as in combination drugs and immunotherapy
  • The changing socio-economic conditions impacting allergic rhinitis drug demand

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape

How the Allergic Rhinitis Drugs Market Forecast 2015-2025: Future Prospects for Companies in Antihistamines, Corticosteroids, immunotherapy & Vaccines report helps you

In summary our 326 page report gives you the following knowledge:

  • Revenues to 2025 for the overall allergic rhinitis drugs market - discover the industry's prospects, finding promising areas for investments and revenues
  • Revenue forecasts to 2025 for 5 product categories (therapeutic classes) within allergic rhinitis drugs - discover forecasts for intranasal antihistamines, oral antihistamines, immunotherapy & vaccines, intranasal corticosteroids and other allergic rhinitis drugs
  • Revenue forecast to 2025 for 12 leading national markets - US, China, Japan, India, Germany, France, UK, Italy, Spain, Russia, Brazil, Mexico, and Rest of the World
  • Assess leading companies - hear about the products, results and strategies, including recent activities, future outlook, and allergic drugs revenue forecast for 8 leading companies, including UCB, Stallergenes, Merck & Co, and Sanofi
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market
  • Opinions from our survey, seeing interviews with industry authorities
  • IP protection and generic drug competition - see what affects product revenue

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Table of Contents

1. Report Overview

  • 1.1 Global
  • 1.1 Global Allergic Rhinitis Drugs: Market Overview
  • 1.2 Global Allergic Rhinitis Drugs Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered By This Analytical Report
  • 1.6 Who Is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. An Introduction To Allergic Rhinitis Drugs

  • 2.1 The Pharmaceutical Industry: A Brief Introduction
    • 2.1.1 Allergic Rhinitis Treatments - An Industry Overview
  • 2.2 A Brief Overview Of Allergy
  • 2.3 Allergic Rhinitis
    • 2.3.1 The Global Prevalence Of Allergic Rhinitis
    • 2.3.2 Pathophysiology Of Allergic Rhinitis: IgEs And Mast Cells
    • 2.3.3 Symptoms Of Allergic Rhinitis
    • 2.3.4 Classification Of Allergic Rhinitis
      • 2.3.4.1 Non-Allergic Rhinitis And Mixed Rhinitis
    • 2.3.5 Seasonal Allergic Rhinitis (Hay Fever)
    • 2.3.6 Perennial Allergic Rhinitis
    • 2.3.7 Diagnosis Of Allergic Rhinitis
  • 2.4 Treatment Of Allergic Rhinitis
    • 2.4.1 Antihistamines
      • 2.4.1.1 First-Generation Antihistamines
      • 2.4.1.2 Second- And Third-Generation Antihistamines
    • 2.4.2 Corticosteroids
      • 2.4.2.1 First-, Second- And Third-Generation Intranasal Corticosteroids
      • 2.4.2.2 Combination Drug Products
    • 2.4.3 Leukotriene Receptor Antagonists
    • 2.4.4 Cromolyn (cromoglicic acid)
    • 2.4.5 Decongestants
    • 2.4.6 Saline Nasal Sprays
    • 2.4.7 Immunotherapy And Vaccines
  • 2.5 Phases Of Clinical Trials
  • 2.6 Scope Of This Report

3. The Global Allergic Rhinitis Drugs Market, 2015-2025

  • 3.1 The Global Allergic Rhinitis Drugs Market: Market Overview
  • 3.2 Categorisation Of The Global Allergic Rhinitis Drugs Market
  • 3.3 The Global Allergic Rhinitis Drugs Market In 2014
  • 3.4 Leading Allergic Rhinitis Drugs, 2015
  • 3.5 The Global Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
  • 3.6 Allergic Rhinitis Drugs: Changing Market Shares By Sector 2015-2025

4. The Intranasal Antihistamines Market: Market Analysis And Forecast 2015-2025

  • 4.1 Leading Products In The Intranasal Antihistamines Market, 2014
  • 4.2 Intranasal Antihistamines: Market Trends And Developments, 2015
    • 4.2.1 Azelastine Versus Olopatadine
    • 4.2.2 Intranasal Combination Products
  • 4.3 Intranasal Antihistamines: Market Forecast 2015-2025
    • 4.3.1 Intranasal Antihistamines: Market Forecast by Volume, 2015-2025
    • 4.3.2 Intranasal Antihistamines: Changing Market Shares By Leading Drugs 2015-2025
  • 4.4 Leading Intranasal Antihistamines
  • 4.5 Patanase (olopatadine) - Novartis
    • 4.5.1 Patanase: Sales Forecast 2015-2025
  • 4.6 Astepro (azelastine) - Meda Pharmaceuticals
    • 4.6.1 Astepro: Sales Forecast 2015-2025
  • 4.7 Astelin (azelastine) - Meda Pharmaceuticals
    • 4.7.1 Astelin: Sales Forecast 2015-2025
  • 4.8 Dymista (azelastine/fluticasone) - Meda Pharmaceuticals
    • 4.8.1 Dymista: Sales Forecast 2015-2025
  • 4.9 Generic Intranasal Azelastine
    • 4.9.1 Generic Intranasal Azelastine: Sales Forecast By Value, 2015-2025
    • 4.9.2 Generic Intranasal Azelastine: Sales Forecast By Volume, 2015-2025
  • 4.10 Generic Intranasal Olopatadine
    • 4.10.1 Generic Intranasal Olopatadine: Sales Forecast By Value, 2015-2025
    • 4.10.2 Generic Intranasal Olopatadine: Sales Forecast By Volume, 2015-2025

5. Intranasal Corticosteroids Market: Market Analysis And Forecast 2015-2025v

  • 5.1 Leading Products In The Intranasal Corticosteroids Market, 2014
  • 5.2 Intranasal Corticosteroids: Market Forecast 2015-2025
    • 5.2.1 Intranasal Corticosteroids: Market Forecast by Volume, 2015-2025
    • 5.2.2 Intranasal Corticosteroids: Changing Market Shares By Leading Drugs 2015-2025
  • 5.3 Leading Intranasal Corticosteroids
  • 5.4 Nasonex (mometasone) - Merck
    • 5.4.1 Nasonex: Sales Forecast by Value, 2015-2025
    • 5.4.2 Nasonex: Sales Forecast by Volume, 2015-2025
  • 5.5 Avamys/Veramyst (fluticasone furoate) - GlaxoSmithKline
    • 5.5.1 Avamys/Veramyst: Sales Forecast by Value, 2015-2025
    • 5.5.2 Avamys/Veramyst: Sales Forecast by Volume, 2015-2025
  • 5.6 Flixonase/Flonase/Flonase-OTC (fluticasone propionate) - GlaxoSmithKline
    • 5.6.1 Flixonase/Flonase/Flonase-OTC: Sales Forecast By Value, 2015-2025
    • 5.6.2 Flixonase/Flonase/Flonase-OTC: Sales Forecast By Volume, 2015-2025
  • 5.7 Rhinocort (budesonide) - AstraZeneca
    • 5.7.1 Rhinocort: Sales Forecast by Value, 2015-2025
    • 5.7.2 Rhinocort: Sales Forecast by Volume, 2015-2025
  • 5.8 Omnaris (ciclesonide) - Dainippon Sumitomo/Takeda
    • 5.8.1 Omnaris: Sales Forecast By Value, 2015-2025
    • 5.8.2 Omnaris: Sales Forecast By Volume, 2015-2025
  • 5.9 Nasacort/Nasacort-OTC (triamcinolone) - Sanofi
    • 5.9.1 Nasacort/Nasacort-OTC: Sales Forecast By Value, 2015-2025
    • 5.9.2 Nasacort: Sales Forecast By Volume, 2015-2025
  • 5.10 Beconase/Beconase AQ (beclometasone) - GlaxoSmithKline/Omega Pharma
    • 5.10.1 Beconase/Beconase AQ: Sales Forecast By Value, 2015-2025
    • 5.10.2 Beconase/Beconase AQ: Sales Forecast by Volume, 2015-2025
  • 5.11 Qnasl (beclometasone) - Teva
    • 5.11.1 Qnasl: Sales Forecast by Value, 2015-2025
    • 5.11.2 Qnasl: Sales Forecast by Volume, 2015-2025
  • 5.12 Zetonna (ciclesonide) - Dainippon Sumitomo
    • 5.12.1 Zetonna: Sales Forecast By Value, 2015-2025
    • 5.12.2 Zetonna: Sales Forecast By Volume, 2015-2025
  • 5.13 Generic Intranasal Corticosteroids
    • 5.13.1 Generic Intranasal Beclometasone
      • 5.13.1.1 Generic Intranasal Beclometasone: Sales Forecast By Value, 2015-2025
      • 5.13.1.2 Generic Intranasal Beclometasone: Sales Forecast By Volume, 2015-2025
    • 5.13.2 Generic Intranasal Budesonide
      • 5.13.2.1 Generic Intranasal Budesonide: Sales Forecast By Value, 2015-2025
      • 5.13.2.2 Generic Intranasal Budesonide: Sales Forecast By Volume, 2015-2025
    • 5.13.3 Generic Intranasal Flunisolide
      • 5.13.3.1 Generic Intranasal Flunisolide: Sales Forecast By Value, 2015-2025
      • 5.13.3.2 Generic Intranasal Flunisolide: Sales Forecast By Volume, 2015-2025
    • 5.13.4 Generic Intranasal Fluticasone
      • 5.13.4.1 Generic Intranasal Fluticasone: Sales Forecast By Value, 2015-2025
      • 5.13.4.2 Generic Intranasal Fluticasone: Sales Forecast By Volume, 2015-2025
    • 5.13.5 Generic Intranasal Mometasone
      • 5.13.5.1 Generic Intranasal Mometasone: Sales Forecast By Value, 2015-2025
      • 5.13.5.2 Generic Intranasal Mometasone: Sales Forecast By Volume, 2015-2025
    • 5.13.6 Generic Intranasal Triamcinolone
      • 5.13.6.1 Generic Intranasal Triamcinolone: Sales Forecast By Value, 2015-2025
      • 5.13.6.2 Generic Intranasal Triamcinolone: Sales Forecast By Volume, 2015-2025

6. Oral Antihistamines Market: Market Analysis And Forecast 2015-2025

  • 6.1 Oral Antihistamines: Market Overview
    • 6.1.1 Leading Products In The Oral Antihistamines Market, 2014
  • 6.2 Oral Antihistamines: Market Trends And Developments, 2015
    • 6.2.1 Patent Expiries And The Threat Of Generics
    • 6.2.2 The Increasing Switch From Prescription To Over-The-Counter Sales
    • 6.2.3 The Potential For Combination Therapy With Intranasal Corticosteroids
  • 6.3 Oral Antihistamines: Market Forecast 2015-2025
    • 6.3.1 Oral Antihistamines: Changing Market Shares By Leading Drugs 2015-2025
  • 6.4 Leading Oral Antihistamines For The Treatment Of Allergic Rhinitis
  • 6.5 Allegra/Allegra-D/Allegra OTC (fexofenadine) - Sanofi
    • 6.5.1 Allegra/Allegra OTC: Historical Sales, 1995-2014
    • 6.5.2 Allegra/Allegra OTC: Sales Forecast 2015-2025
  • 6.6 Zyrtec/Zyrtec D (cetirizine) - Johnson & Johnson/ UCB/ GSK
    • 6.6.1 Zyrtec/Zyrtec D: Sales Forecast 2015-2025
  • 6.7 Claritin/Claritin OTC (loratadine) - Bayer/ Merck & Co
    • 6.7.1 Claritin/Claritin OTC: Sales Forecast 2015-2025
  • 6.8 Xyzal (levocetirizine) - Sanofi/ UCB/ GSK
    • 6.8.1 Xyzal: Sales Forecast 2015-2025
  • 6.9 Allelock (olopatadine) - Kyowa Hakko Kirin
    • 6.9.1 Allelock: Sales Forecast 2015-2025
  • 6.10 Clarinex (desloratadine) - Merck & Co.
    • 6.10.1 Clarinex: Sales Forecast 2015-2025
  • 6.11 Ebastel (ebastine) - AstraZeneca/Takeda/Dainippon Sumitomo
    • 6.11.1 Ebastel: Sales Forecast 2015-2025
  • 6.12 Talion (bepotastine) - Mitsubishi Tanabe
    • 6.12.1 Talion: Sales Forecast 2015-2025
  • 6.13 Other Oral Antihistamines: Sales Forecast 2015-2025

7. Immunotherapy And Vaccines: Market Analysis And Forecast 2015-2025

  • 7.1 Immunotherapy And Vaccines: Market Overview
    • 7.1.1 Immunotherapy: Primed For Rapid Expansion
  • 7.2 Leading Immunotherapy Products In The Allergic Rhinitis Market, 2014
  • 7.3 Allergic Rhinitis Immunotherapy: Market Trends And Developments, 2015
    • 7.3.1 Subcutaneous And Sublingual Immunotherapy
    • 7.3.2 Expansion Into The US Market
    • 7.3.3 Standardisation Of Immunotherapy Products
    • 7.3.4 Immunotherapy As A Preventative Treatment
  • 7.4 Allergic Rhinitis Immunotherapy: Market Forecast 2015-2025
    • 7.4.1 Allergic Rhinitis Immunotherapy: Changing Market Shares By Leading Products 2015-2025
  • 7.5 Immunotherapy Type - By Route Of Administration, 2014
  • 7.6 Leading Immunotherapy Products For Allergic Rhinitis
  • 7.7 Staloral (Grass pollen allergen extract) - Stallergenes
    • 7.7.1 Staloral: Sales Forecast 2015-2025
  • 7.8 Alutard SQ (Grass pollen allergen extract) - ALK-Abelló
    • 7.8.1 Alutard SQ: Sales Forecast 2015-2025
  • 7.9 Grazax/Grastek (Timothy grass pollen allergen extract) - ALK-Abelló/Merck
    • 7.9.1 Grazax/Grastek: Sales Forecast 2015-2025
  • 7.10 Oralair (Grass pollen allergen extract) - Stallergenes/Greer
    • 7.10.1 Oralair: Sales Forecast 2015-2025
  • 7.11 Ragwitek (Short ragweed pollen allergen extract) - Merck
    • 7.11.1 Ragwitek: Sales Forecast 2015-2025
  • 7.12 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast 2015-2025

8. Leading National Markets For Allergic Rhinitis Drugs, 2015-2025

  • 8.1 The Allergic Rhinitis Drugs Market By Region
    • 8.1.1 The Global Distribution Of Allergic Rhinitis Drugs In 2014
  • 8.2 Leading National Markets: Forecast 2015-2025
    • 8.2.1 Changing Market Shares By Region, 2015-2025
  • 8.3 Regional Allergic Rhinitis Drugs Markets: Analysis And Forecasts, 2015-2025
  • 8.4 United States: The Largest Allergic Rhinitis Drugs Market
    • 8.4.1 US Allergic Rhinitis Drugs Market: Trends And Developments
    • 8.4.1.1 The Trend Of Rx-to-OTC Switching
    • 8.4.2 US Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
  • 8.5 EU5
    • 8.5.1 EU5 Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
      • 8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
    • 8.5.2 Germany
      • 8.5.2.1 Germany: Reform Of AMNOG Pharmaceutical Rebate Law
      • 8.5.2.2 German Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
    • 8.5.3 UK
      • 8.5.3.1 UK: Increasing Burden Of Allergy
      • 8.5.3.2 UK Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
    • 8.5.4 France
      • 8.5.4.1 France: Social Security Finance Act 2015
      • 8.5.4.2 French Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
    • 8.5.5 Italy
      • 8.5.5.1 Italy: Government Cost Cutting Measures Impacting Market Growth
      • 8.5.5.2 Italian Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
    • 8.5.6 Spain
      • 8.5.6.1 Spanish Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
  • 8.6 China
    • 8.6.1 Air Pollution Associated With Increasing Prevalence
    • 8.6.2 Expansion Of Healthcare Coverage And Reimbursement In China
    • 8.6.3 Chinese Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
  • 8.7 Japan
    • 8.7.1 Cedar Reforestation And The Hay Fever Epidemic
    • 8.7.2 Genetically Modified Rice As Immunotherapy
    • 8.7.3 Effects Of The Rising Levels Of Generic Drug Penetration
    • 8.7.4 Japanese Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
  • 8.8 Russia
    • 8.8.1 How Will Russia's Economic Status Affect Its Pharma Industry?
    • 8.8.2 Russian Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
  • 8.9 India
    • 8.9.1 The Impact Of The Drug Prices Control Order On Indian Pharma
    • 8.9.2 India's Expansion Of Healthcare Provision
    • 8.9.3 Indian Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
  • 8.10 Brazil
    • 8.10.1 How Will Brazil's Growing Healthcare Influence Allergic Rhinitis Drugs
    • 8.10.2 Brazilian Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
  • 8.11 Mexico
    • 8.11.1 Are Multinationals Waking Up To Mexico's Market Potential?
    • 8.11.2 Mexican Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
  • 8.12 Rest of the World
    • 8.12.1 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast 2015-2025

9. Leading Companies In The Allergic Rhinitis Drugs Market, 2015-2025

  • 9.1 Allergic Rhinitis Drugs - An Evolving Market Space
    • 9.1.1 Leading Companies In The Allergic Rhinitis Drugs Market, 2015
    • 9.1.2 Allergic Rhinitis Drugs Market: Leading Companies Forecast 2015-2025
    • 9.1.3 Allergic Rhinitis Drugs: Changing Market Shares By Leading Companies 2015-2025
  • 9.2 ALK-Abelló
    • 9.2.1 ALK-Abelló: Allergic Rhinitis Drugs Portfolio, 2015
    • 9.2.2 ALK-Abelló: Recent Developments
      • 9.2.2.1 Progress In The Approval Process For House Dust Mite (HDM) SLIT-Tablet
      • 9.2.2.2 ALK Collaborates With EddingPharm To Boost China Sales
      • 9.2.2.3 Jext Product Recall And The Subsequent Recovery
    • 9.2.3 ALK-Abelló: Sales Forecast 2015-2025
    • 9.2.4 ALK-Abelló: Allergic Rhinitis Drug Development Pipeline, 2015
  • 9.3 GlaxoSmithKline (GSK)
    • 9.3.1 GlaxoSmithKline: Allergic Rhinitis Drugs Portfolio, 2015
    • 9.3.2 GlaxoSmithKline: Recent Developments
      • 9.3.2.1 GSK Asset Swap with Novartis To Restructure Consumer Health
      • 9.3.2.2 GSK Divestment of OTC Products
    • 9.3.3 GlaxoSmithKline: Sales Forecast 2015-2025
    • 9.3.4 GlaxoSmithKline: Allergic Rhinitis Drug Development Pipeline, 2015
  • 9.4 Johnson & Johnson
    • 9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs Portfolio, 2015
    • 9.4.2 Johnson & Johnson: Recent Developments
      • 9.4.2.1 Launch of Zyrtec Dissolve Tabs
      • 9.4.2.2 Manufacturing Recalls At McNeil Consumer Healthcare
    • 9.4.3 Johnson & Johnson: Sales Forecast 2015-2025
  • 9.5 Kyowa Hakko Kirin
    • 9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Portfolio, 2015
    • 9.5.2 Kyowa Hakko Kirin: Sales Forecast 2015-2025
  • 9.6 Merck & Co.
    • 9.6.1 Merck: Allergic Rhinitis Drugs Portfolio, 2015
    • 9.6.2 Merck: Recent Developments
    • 9.6.2.1 Bayer Acquires Merck's Consumer Health Business
    • 9.6.2.2 FDA Rejects Singulair OTC Switch
    • 9.6.3 Merck: Sales Forecast 2015-2025
    • 9.6.4 Merck: Allergic Rhinitis Drug Development Pipeline, 2015
  • 9.7 Sanofi
    • 9.7.1 Sanofi: Allergic Rhinitis Drugs Portfolio, 2015
    • 9.7.2 Sanofi: Sales Forecast 2015-2025
  • 9.8 Stallergenes
    • 9.8.1 Stallergenes: Allergic Rhinitis Drugs portfolio, 2015
    • 9.8.2 Stallergenes: Recent Developments
      • 9.8.2.1 Stallergenes Acquires Argentinean Company Alergo Pharma
      • 9.8.2.2 Greer Launches Oralair In The US
      • 9.8.2.3 Proposed Merger With Greer
    • 9.8.3 Stallergenes: Sales Forecast 2015-2025
    • 9.8.4 Stallergenes: Allergic Rhinitis Drug Development Pipeline, 2015
  • 9.9 UCB
    • 9.9.1 UCB: Allergic Rhinitis Drugs Portfolio, 2015
    • 9.9.2 UCB: Sales Forecast 2015-2025
  • 9.10 Other Leading Companies Within The Allergic Rhinitis Drugs Market

10. Allergic Rhinitis Drugs: Research And Development Pipeline, 2015-2025

  • 10.1 Trends And Developments In The Allergic Rhinitis Pipeline
  • 10.2 The R&D Pipeline For Oral Antihistamine, 2015
    • 10.2.1 Talion (bepotastine) - Mitsubishi Tanabe
    • 10.2.2 ZPL-3893787 (histamine H4R antagonist) - Ziarco Pharma
    • 10.2.3 ZPL-868087 (oral histamine H3R antagonist) - Ziarco Pharma
  • 10.3 The R&D Pipeline For Intranasal Corticosteroids, 2015
    • 10.3.1 APC-3000 (HFA inhaled corticosteroid) - Adamis Pharmaceuticals
    • 10.3.2 S0597 (topical glucocorticoid) - Sun Pharmaceuticals
    • 10.3.3 TBS-6 - Trimel Pharmaceuticals
  • 10.4 The R&D Pipeline For Immunotherapy In Allergic Rhinitis, 2015
    • 10.4.1 Actair (house dust mite SLIT; STG320) - Stallergenes/Shionogi & Co
    • 10.4.2 AllerT (subcutaneous birch pollen immunotherapy) - Anergis
    • 10.4.3 Cat-SPIRE and other -SPIRE Therapies (synthetic peptide immunoregulatory epitopes) - Circassia Pharmaceuticals
    • 10.4.4 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma
    • 10.4.5 House Dust Mite SLIT-Tablet (MK-8237) - ALK-Abelló/Merck/Torii
    • 10.4.6 Pollinex Quattro (subcutaneous immunotherapies) - Allergy Therapeutics
    • 10.4.7 gp-ASIT+ (grass pollen allergen fragments) - Biotech Tools
    • 10.4.8 Betula verrucosa (Bet v) 1 allergen - Stallergenes
  • 10.5 The R&D Pipeline for Other Allergic Rhinitis Drugs
    • 10.5.1 eN-Lac (Lactobacillus paracasei GMNL-32) - GenMont Biotech
    • 10.5.2 S-555739 (prostaglandin D2 receptor antagonist) - Shionogi
    • 10.5.3 DSP-3025/AZD-8848 (toll-like receptor 7 agonist) - Dainippon Sumitomo/ AstraZeneca
    • 10.5.4 GSK2245035 (toll-like receptor 7 agonist) - GSK
    • 10.5.5 HP-3060 (transdermal long-acting tape) - Hisamitsu
    • 10.5.6 MRX-4 (anti-inflammatory agent) - Celsus Therapeutics
    • 10.5.7 OC459 (OC000459) - Oxagen/ Atopix Therapeutics /Eleventa
    • 10.5.8 ONO-4053 (prostaglandin D2 receptor antagonist) - Ono Pharmaceutical
    • 10.5.9 WF10 (tetrachlorodecaoxygen chlorite matrix) - Nuvo Research
    • 10.5.10 RPL554 (PDE-3/PDE-4 antagonist) - Verona Pharma
    • 10.5.11 VTX-1463 (toll-like receptor 8 agonist) - VentiRx

11. Qualitative Analysis Of The Allergic Rhinitis Drugs Market, 2015-2025

  • 11.1 Market Factors Influencing Allergic Rhinitis Drugs
  • 11.2 SWOT Analysis Of The Global Allergic Rhinitis Drugs Market, 2015-2025
    • 11.2.1 Strengths
      • 11.2.1.1 OTC-Switch Facilitating Ease Of Consumer Access
      • 11.2.1.2 The Established Role Of Allergic Rhinitis Drugs In Treatment
      • 11.2.1.3 Allergic Rhinitis And The Rising Unmet Clinical Need
      • 11.2.1.4 Rising Profile of Allergic Rhinitis In Various Regions Driving Healthcare Provision
    • 11.2.2 Weaknesses
      • 11.2.2.1 Intranasal Corticosteroids And Patients' Satisfaction Rates
      • 11.2.2.2 Increasing Penetration Of Generic Drug Products
      • 11.2.2.3 The Challenge Raised By The Low Volume Of Pipeline Developments
    • 11.2.3 Opportunities
      • 11.2.3.1 Growth In Emerging Markets Outstripping Established Markets
      • 11.2.3.2 Rx-to-OTC Switching And The Effects On Revenue Potential
      • 11.2.3.3 Combination Drug Products Providing Rising Efficacy Profiles
      • 11.2.3.4 The Emergence Of Immunotherapy In Allergic Rhinitis
    • 11.2.4 Threats
      • 11.2.4.1 Cost-Containment As A Growth Restraint
      • 11.2.4.2 Rising Cost Of APIs And Manufacturing
      • 11.2.4.3 Patent Expiries And The Resultant Loss Of Revenue
  • 11.3 Porter's Five Force Analysis Of The Global Allergic Rhinitis Drugs Market, 2015-2025
    • 11.3.1 Power of Buyers
    • 11.3.2 Power Of Suppliers
    • 11.3.3 Threat of Substitutes
    • 11.3.4 Threat Of New Entrants
    • 11.3.5 Rivalry Among Competitors

12. Expert Opinions From Our Primary Research

  • 12.1 Interview with Tonya Winders, President and Chief Executive Officer, Allergy & Asthma Network
    • 12.1.1 Allergy and Asthma Network And The Organisation's Work In Allergic Rhinitis
    • 12.1.2 Education Efforts Being Implement By Allergy & Asthma Network
    • 12.1.3 Changing Conditions And The Impact On Allergic Rhinitis Prevalence And Severity
    • 12.1.4 Climatic Changes And Its Impact On Allergic Rhinitis Incidence
    • 12.1.5 Immunotherapy - Regulatory Hurdles And Its Adoption
    • 12.1.6 Future Trends - Immunotherapies, Regulatory Approvals, Reimbursement
    • 12.1.7 Allergy & Asthma Network's Plans For The Future
  • 12.2 Interview with Amena Warner, Nurse Advisor at Allergy UK And President, International Nurses Group In Immunodeficiencies
    • 12.2.1 Allergy UK And The Organisation's Work In Allergic Rhinitis
    • 12.2.2 Allergy UK's Patient Education Efforts
    • 12.2.3 The Challenges Associated With The Treatment Options Available To Allergic Rhinitis Patients
    • 12.2.4 Familial And Environmental Factors Influencing Allergic Rhinitis Prevalence
    • 12.2.5 Immunotherapy And Its Impact On The Treatment Landscape For Allergic Rhinitis
    • 12.2.6 Sublingual Immunotherapies And The Expanding Repertoire Of Allergic Rhinitis Treatments
    • 12.2.7 Allergy UK's Future Plans In Patient Education And Treatment Access
  • 12.3 Interview with Dr Apelles Econs MRCS LRCP, Consultant - Allergy & Nutrition, Allergy Medical UK
    • 12.3.1 On The Aetiology And Progression Of Allergy And Allergic Conditions
    • 12.3.2 Factors Driving Allergic Rhinitis And The Familial Link
    • 12.3.3 Developments And New Technologies In Diagnosing Allergies
    • 12.3.4 Future Trends In Allergic Rhinitis Treatment And Allergy Medical UK's Plans For The Future

13. Conclusions

  • 13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
  • 13.2 Leading Sectors In The Allergic Rhinitis Drugs Market In 2014
  • 13.3 Leading Regions In The Allergic Rhinitis Drugs Market In 2014
  • 13.4 Leading Companies In The Allergic Rhinitis Drugs Market, 2014
  • 13.5 What Does The Future Hold For Allergic Rhinitis Drugs?

List of Tables

  • Table 1.1 Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Country, 2014-2025 (Redacted Data)
  • Table 2.1 Leading Antihistamines for Allergic Rhinitis, 2015
  • Table 2.2 Leading Corticosteroids for Allergic Rhinitis, 2015
  • Table 2.3 Clinical Trial Phases
  • Table 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2014
  • Table 3.2 Top 10 Allergic Rhinitis Drugs: Revenue ($m) and Market Share (%) ,2014
  • Table 3.3 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 3.4 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Sector, 2014-2019, 2019-2025, 2014-2025
  • Table 3.5 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2014, 2019, 2025
  • Table 4.1 Top Drugs In The Intranasal Antihistamines Market: Revenue ($m) and Market Shares (%), 2014
  • Table 4.2 Intranasal Antihistamines Market: Market Forecast by Value ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 4.3 Intranasal Antihistamines Market: Market Forecast by Volume (Million Sprays, AGR%, CAGR%) by Leading Drug Types, 2014-2025
  • Table 4.4 The Global Intranasal Antihistamines Market: Market Share (%) by Value by Leading Drugs, 2014, 2019, 2025
  • Table 4.5 Patanase: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.6 Astepro: Meda Pharma Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.7 Astelin: Meda Pharma Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.8 Dymista: Meda Pharma Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.9 Generic Intranasal Azelastine: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 4.10 Generic Intranasal Azelastine: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 4.11 Generic Intranasal Olopatadine: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 4.12 Generic Intranasal Olopatadine: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m) and Market Shares (%), 2014
  • Table 5.2 Intranasal Corticosteroids Market: Market Forecast by Value ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 5.3 Intranasal Corticosteroids Market: Market Forecast by Volume (Million Sprays, AGR%, CAGR%) by Leading Drug Types, 2014-2025
  • Table 5.4 The Global Intranasal Corticosteroids Market: Market Share by Value (%) by Leading Drugs, 2014, 2019, 2025
  • Table 5.5 Nasonex: Merck Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.6 Nasonex: Merck Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.7 Avamys/Veramyst: GlaxoSmithKline Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.8 Avamys/Veramyst: GlaxoSmithKline Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.9 Flixonase/Flonase/Flonase-OTC: GlaxoSmithKline Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.10 Flixonase/Flonase/Flonase-OTC: GlaxoSmithKline Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.11 Rhinocort: AstraZeneca Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.12 Rhinocort: AstraZeneca Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.13 Omnaris: Dainippon Sumitomo/Takeda Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.14 Omnaris: Dainippon Sumitomo/Takeda Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.15 Nasacort/Nasacort-OTC: Sanofi Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.16 Nasacort/Nasacort-OTC: Sanofi Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.17 Beconase/Beconase AQ: GSK/Omega Pharma Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.18 Beconase/Beconase AQ: GSK/Omega Pharma Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.19 Qnasl: Teva Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.20 Qnasl: Teva Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.21 Zetonna: Dainippon Sumitomo Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.22 Zetonna: Dainippon Sumitomo Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.23 Generic Intranasal Beclometasone: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.24 Generic Intranasal Beclometasone: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.25 Generic Intranasal Budesonide: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.26 Generic Intranasal Budesonide: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.27 Generic Intranasal Flunisolide: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.28 Generic Intranasal Flunisolide: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.29 Generic Intranasal Fluticasone: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.30 Generic Intranasal Fluticasone: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.31 Generic Intranasal Mometasone: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.32 Generic Intranasal Mometasone: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 5.33 Generic Intranasal Triamcinolone: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
  • Table 5.34 Generic Intranasal Triamcinolone: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
  • Table 6.1 Leading Oral Antihistamines: Revenues ($m) and Market Shares (%), 2014
  • Table 6.2 Oral Antihistamines Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 6.3 The Global Oral Antihistamines Market: Market Share by Value (%) by Leading Drugs, 2014, 2019, 2025
  • Table 6.4 Allegra/Allegra-D/Allegra OTC: Sanofi Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.5 Zyrtec/Zyrtec-D: J&J/ UCB/ GSK Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.6 Claritin/Claritin OTC: Merck & Co/ Bayer Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.7 Xyzal: Sanofi/ UCB/ GSK Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.8 Allelock: Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.9 Clarinex: Merck Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.10 Ebastel: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.11 Talion: Mitsubishi Tanabe Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.12 Other Oral Antihistamines: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.1 Leading Allergic Rhinitis Immunotherapy Products: Revenues ($m) and Market Shares (%), 2014
  • Table 7.2 Allergic Rhinitis Immunotherapy: Market Forecast ($m, AGR%, CAGR%) by Leading Products, 2014-2025
  • Table 7.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share by Value (%) by Leading Products, 2014, 2019, 2025
  • Table 7.4 Allergic Rhinitis Immunotherapy Market: Revenue ($m) and Market Share (%) by Immunotherapy Type, 2014
  • Table 7.5 Staloral: Stallergenes Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.6 Alutard SQ: ALK-Abelló Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.7 Grazax/Grastek: ALK-Abelló/Merck Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.8 Oralair: Stallergenes Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.9 Ragwitek: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.10 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.1 The Global Allergic Rhinitis Drugs Market: Market Size ($m) and Market Share (%) by Region, 2014
  • Table 8.2 Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025
  • Table 8.3 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Region, 2014-2019, 2019-2025, and 2014-2025
  • Table 8.4 The Global Allergic Rhinitis Drugs Market Forecast: Market Share (%) by Region, 2014, 2019, and 2025
  • Table 8.5 The US Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.6 US Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.7 The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025
  • Table 8.8 The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and Market Share (%) by Country 2014
  • Table 8.9 The EU5 Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.10 The EU5 Allergic Rhinitis Drugs Market: Market Share (%) by Country, 2014, 2019, 2025
  • Table 8.11 The German Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.12 German Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.13 The UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.14 UK Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.15 The French Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.16 French Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.17 The Italian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.18 Italian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.19 The Spanish Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.20 Spanish Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.21 The Chinese Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.22 Chinese Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.23 The Japanese Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.24 Japanese Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.25 The Russian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.26 Russian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.27 The Indian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.28 Indian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.29 The Brazilian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.30 Brazilian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.31 The Mexican Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.32 Mexican Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.33 The Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025
  • Table 8.34 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.1 Leading Companies In The Allergic Rhinitis Drug Market: Revenues ($m) and Market Shares (%), 2014
  • Table 9.2 Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2014-2025
  • Table 9.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Leading Companies, 2014, 2019, 2025
  • Table 9.4 ALK- Abelló: Company Overview, 2015
  • Table 9.5 ALK-Abelló: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.6 GlaxoSmithKline: Company Overview, 2015
  • Table 9.7 GlaxoSmithKline: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.8 Johnson & Johnson: Company Overview, 2015
  • Table 9.9 Johnson & Johnson: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.10 Kyowa Hakko Kirin: Company Overview, 2015
  • Table 9.11 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.12 Merck & Co: Company Overview, 2015
  • Table 9.13 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.14 Sanofi: Company Overview, 2015
  • Table 9.15 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.16 Stallergenes: Company Overview, 2015
  • Table 9.17 Stallergenes: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.18 UCB: Company Overview, 2015
  • Table 9.19 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 10.1 Allergic Rhinitis: Oral Antihistamine Pipeline, 2015
  • Table 10.2 Allergic Rhinitis: Intranasal Corticosteroids Pipeline, 2015
  • Table 10.3 Allergic Rhinitis: Immunotherapy Pipeline, 2015
  • Table 10.4 Allergic Rhinitis: Other Pipeline Drugs, 2015
  • Table 11.1 SWOT Analysis of the Global Allergic Rhinitis Drugs Market, 2015-2025
  • Table 13.1 Global Allergic Rhinitis Drugs: Market Forecast ($m, CAGR%), 2014, 2018, 2021, 2025
  • Table 13.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m) by Region, 2014, 2018, 2021, 2025

List of Figures

  • Figure 1.1 Global Allergic Rhinitis Drugs Market: Market Sectors, 2015
  • Figure 1.2 Italian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) 2014-2025 (Illustrative Data)
  • Figure 2.1 Role of Mast Cells and IgE in Allergic Rhinitis, 2015
  • Figure 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) by Sector, 2014
  • Figure 3.2 Top 10 Allergic Rhinitis Drugs: Market Shares (%), 2014
  • Figure 3.3 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) by Sector, 2014-2025
  • Figure 3.4 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Sector, 2014-2019
  • Figure 3.5 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Sector, 2019-2025
  • Figure 3.6 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Sector, 2014-2025
  • Figure 3.7 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2014
  • Figure 3.8 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2019
  • Figure 3.9 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2025
  • Figure 4.1 Top Drugs In The Intranasal Antihistamines Market: Revenue ($m), 2014
  • Figure 4.2 Intranasal Antihistamines Market: Market Forecast by Value ($m, AGR%), 2014-2025
  • Figure 4.3 Intranasal Antihistamines Market: Revenue Forecast by Value ($m) by Leading Drugs, 2014-2025
  • Figure 4.4 Intranasal Antihistamines Market: Market Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 4.5 Intranasal Antihistamines Market: Sales Forecast (Million Sprays) by Leading Drug Types, 2014-2025
  • Figure 4.6 The Global Intranasal Antihistamines Market by Volume: Market Share (%) by Leading Drugs, 2014
  • Figure 4.7 The Global Intranasal Antihistamines Market by Volume: Market Share (%) by Leading Drugs, 2019
  • Figure 4.8 The Global Intranasal Antihistamines Market by Volume: Market Share (%) by Leading Drugs, 2025
  • Figure 4.9 Patanase: Novartis Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.10 Astepro: Meda Pharma Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.11 Astelin: Meda Pharma Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.12 Dymista: Meda Pharma Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.13 Generic Intranasal Azelastine: Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 4.14 Generic Intranasal Azelastine: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 4.15 Generic Intranasal Olopatadine: Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 4.16 Generic Intranasal Olopatadine: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m), 2014
  • Figure 5.2 Intranasal Corticosteroids Market: Market Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.3 Intranasal Corticosteroids Market: Market Forecast by Value ($m) by Leading Drugs, 2014-2025
  • Figure 5.4 Intranasal Corticosteroids Market: Market Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.5 Intranasal Corticosteroids Market: Revenue Forecast by Volume (Million Sprays) by Leading Drug Types, 2014-2025
  • Figure 5.6 The Global Intranasal Corticosteroids Market: Market Share by Value (%) by Leading Drugs, 2014
  • Figure 5.7 The Global Intranasal Corticosteroids Market: Market Share by Value (%) by Leading Drugs, 2019
  • Figure 5.8 The Global Intranasal Corticosteroids Market: Market Share by Value (%) by Leading Drugs, 2025
  • Figure 5.9 Nasonex: Merck Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.10 Nasonex: Merck Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.11 Avamys/Veramyst: GlaxoSmithKline Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.12 Avamys/Veramyst: GlaxoSmithKline Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.13 Flixonase/Flonase/Flonase-OTC: GlaxoSmithKline Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.14 Flixonase/Flonase/Flonase-OTC: GlaxoSmithKline Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.15 Rhinocort: AstraZeneca Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.16 Rhinocort: AstraZeneca Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.17 Omnaris: Dainippon Sumitomo/Takeda Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.18 Omnaris: Dainippon Sumitomo/Takeda Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.19 Nasacort/Nasacort-OTC: Sanofi Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.20 Nasacort/Nasacort-OTC: Sanofi Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.21 Beconase/Beconase AQ: GSK/Omega Pharma Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.22 Beconase/Beconase AQ: GSK/Omega Pharma Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.23 Qnasl: Teva Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.24 Qnasl: Teva Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.25 Zetonna: Dainippon Sumitomo Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.26 Zetonna: Dainippon Sumitomo Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.27 Generic Intranasal Beclometasone: Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.28 Generic Intranasal Beclometasone: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.29 Generic Intranasal Budesonide: Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.30 Generic Intranasal Budesonide: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.31 Generic Intranasal Flunisolide: Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.32 Generic Intranasal Flunisolide: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.33 Generic Intranasal Fluticasone: Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.34 Generic Intranasal Fluticasone: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.35 Generic Intranasal Mometasone: Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.36 Generic Intranasal Mometasone: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 5.37 Generic Intranasal Triamcinolone: Sales Forecast by Value ($m, AGR%), 2014-2025
  • Figure 5.38 Generic Intranasal Triamcinolone: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
  • Figure 6.1 Leading Oral Antihistamines: Revenue ($m), 2014
  • Figure 6.2 Oral Antihistamines Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 6.3 Oral Antihistamines Market: Market Forecast ($m) by Leading Drugs, 2014-2025
  • Figure 6.4 The Global Oral Antihistamines Market: Market Share by Value (%) by Leading Drugs, 2014
  • Figure 6.5 The Global Oral Antihistamines Market: Market Share by Value (%) by Leading Drugs, 2019
  • Figure 6.6 The Global Oral Antihistamines Market: Market Share by Value (%) by Leading Drugs, 2025
  • Figure 6.7 Allegra (Allegra Rx and Allegra OTC) Historical Sales ($m, AGR%),1995-2014
  • Figure 6.8 Allegra/Allegra-D/Allegra OTC: Sanofi Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.9 Zyrtec/Zyrtec-D: J&J/ UCB/ GSK Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.10 Claritin/Claritin OTC: Merck & Co/ Bayer Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.11 Xyzal: Sanofi/ UCB/ GSK Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.12 Allelock: Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.13 Clarinex: Merck Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.14 Ebastel: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.15 Talion: Mitsubishi Tanabe Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.16 Other Oral Antihistamines: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m), 2014
  • Figure 7.2 Allergic Rhinitis Immunotherapy: Market Forecast ($m, AGR%), 2014-2025
  • Figure 7.3 Allergic Rhinitis Immunotherapy: Market Forecast ($m) by Leading Products, 2014-2025
  • Figure 7.4 The Global Allergic Rhinitis Immunotherapy Market: Market Share by Value (%) by Leading Products, 2014
  • Figure 7.5 The Global Allergic Rhinitis Immunotherapy Market: Market Share by Value (%) by Leading Products, 2019
  • Figure 7.6 The Global Allergic Rhinitis Immunotherapy Market: Market Share by Value (%) by Leading Products, 2025
  • Figure 7.7 Allergic Rhinitis Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2014
  • Figure 7.8 Staloral: Stallergenes Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.9 Alutard SQ: ALK-Abelló Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.10 Grazax/Grastek: ALK-Abelló/Merck Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.11 Oralair: Stallergenes Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.12 Ragwitek: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.13 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 8.1 The Global Allergic Rhinitis Drugs Market: Market Size ($m) by Region, 2014
  • Figure 8.2 US, EU5, China and Japan Allergic Rhinitis Drugs Market: Market Forecast ($m), 2014-2025
  • Figure 8.3 Brazil, Russia, India, and Mexico Allergic Rhinitis Drugs Market: Market Forecast ($m), 2014-2025
  • Figure 8.4 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Region, 2014-2019
  • Figure 8.5 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Region, 2019-2025
  • Figure 8.6 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Region, 2014-2025
  • Figure 8.7 The Global Allergic Rhinitis Drugs Market Forecast: Market Share (%) by Region, 2014
  • Figure 8.8 The Global Allergic Rhinitis Drugs Market Forecast: Market Share (%) by Region, 2019
  • Figure 8.9 The Global Allergic Rhinitis Drugs Market Forecast: Market Share (%) by Region, 2025
  • Figure 8.10 US Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.11 The EU5 Allergic Rhinitis Drugs Market: Revenue ($m) by Country, 2014
  • Figure 8.12 Germany, France, UK, Italy, and Spain Allergic Rhinitis Drugs Market: Market Forecast ($m), 2014-2025
  • Figure 8.13 The EU5 Allergic Rhinitis Drugs Market: Market Share (%) by Country, 2014
  • Figure 8.14 The EU5 Allergic Rhinitis Drugs Market: Market Share (%) by Country, 2019
  • Figure 8.15 The EU5 Allergic Rhinitis Drugs Market: Market Share (%) by Country, 2025
  • Figure 8.16 German Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.17 UK Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.18 French Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.19 Italian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.20 Spanish Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.21 Chinese Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.22 Japanese Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.23 Russian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.24 Indian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.25 Brazilian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.26 Mexican Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.27 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 9.1 Leading Companies In The Allergic Rhinitis Drug Market: Revenues ($m), 2014
  • Figure 9.2 Allergic Rhinitis Drugs Market: Market Forecast ($m) by Leading Companies, 2014-2025
  • Figure 9.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Leading Companies, 2014
  • Figure 9.4 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Leading Companies, 2019
  • Figure 9.5 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Leading Companies, 2025
  • Figure 9.6 ALK-Abelló: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.7 GlaxoSmithKline: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.8 Johnson & Johnson: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.9 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.10 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.11 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.12 Stallergenes: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.13 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 11.1 Porter's Five Force Analysis of the Allergic Rhinitis Drugs Market, 2015
  • Figure 13.1 Global Allergic Rhinitis Drugs: Market Forecast ($m), 2014, 2018, 2021, 2025
  • Figure 13.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m) by Region, 2014-2025

Companies Listed

  • ActoGeniX
  • Adamis Pharmaceuticals
  • Alergo Pharma
  • ALK- Abelló
  • Allergy Medical UK
  • Allergy Therapeutics
  • Almirall
  • Altana Pharma (Nycomed)
  • Ampio Pharmaceuticals
  • Anergis
  • Apotex
  • Ares Life Sciences
  • Aspen Pharmacare
  • AstraZeneca
  • Atopix Therapeutics
  • Barr Laboratories
  • Bausch & Lomb
  • Belcher Pharmaceuticals
  • Biotech Tools
  • Catalent Pharma Solutions
  • Celsus Therapeutics
  • Circassia Pharmaceuticals
  • Dainippon Sumitomo
  • DBV Technologies
  • Dr Reddy's Laboratories
  • Eddingpharm
  • Eleventa
  • Fountain Biopharma
  • GenMont Biotech
  • Genzyme (Sanofi)
  • GlaxoSmithKline
  • GlycoMar Limited
  • Greer Laboratories
  • Hi Tech Pharma
  • Hisamitsu Pharmaceutical Co
  • Hoechst AG
  • Human Genome Sciences
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Kalypsys
  • Keldman Healthcare
  • Kyowa Hakko Kirin
  • Leti Pharma (Laboratorios Leti)
  • Lupin Pharmaceuticals
  • Meda Pharma
  • Medpointe Inc (Meda Pharma)
  • Merck & Co
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Nektar Therapeutics
  • Nippon Paper Group
  • Novartis
  • Nuvo Research
  • Omega Pharma
  • Ono Pharmaceutical
  • Oxagen
  • Perrigo
  • Pfizer
  • ProStrakan (Kyowa Hakko Kirin)
  • Reckitt Benckiser
  • Roxane Laboratories (Boehringer Ingelheim)
  • Sanofi
  • Schering-Plough (Merck)
  • Shionogi & Co Ltd
  • Stallergenes
  • Sun Pharmaceuticals
  • Sunovion Pharmaceuticals (Dainippon Sumitomo)
  • Takeda
  • Teva Pharmaceuticals
  • Trimel Pharmaceuticals
  • Ube Industries
  • UCB
  • VentiRx
  • Verona Pharma
  • ViiV Healthcare
  • Wockhardt
  • Ziarco Pharma

Organisations Mentioned In The Report

  • Allergy & Asthma Network
  • AllergyUK
  • American Academy of Allergy, Asthma and Immunology (AAAAI)
  • British Society for Allergy & Clinical Immunology (BSACI) [UK]
  • Farmácia Popular [Brazil]
  • Imperial College London
  • International Nurses Group In Immunodeficiencies
  • Japanese Ministry of Health, Labour and Welfare
  • Les Entreprises Du Médicament (Leem) [France]
  • National Development and Reform Commission (NDRC) [China]
  • National Pharmaceutical Pricing Authority (NPPA) [India]
  • PollenUK
  • The Pharmaceutical Research and Manufacturers of America (PhRMA)
  • The UK Health and Social Care Information Centre
  • Université Libre de Bruxelles [Belgium]
  • University of Leuven [Belgium]
  • US Attorney's Office for the Eastern District of Pennsylvania
  • US Food and Drug Administration (FDA)
  • World Allergy Organisation
  • World Health Organisation (WHO)
Back to Top